Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Lack of Assurance of Sterility.
Consumers and healthcare providers should stop using this product immediately. Contact Bristol-Myers Squibb Company or your healthcare provider for guidance. Notification method: Letter
Opdualag injection (Nivolumab and Relatlimab-rmbw) comes in 240 mg and 80 mg/20 mL single-dose vials. The recalled lot number is 033A23B, with an expiration date of April 30, 2026.
The recall is due to a lack of assurance of sterility, which poses a high risk of infection. Sterility is critical for injectable medications.
No specific incidents of injury or illness have been reported related to this recall. The lack of sterility could potentially lead to serious health risks.
Stop using the Opdualag injection immediately. Contact Bristol-Myers Squibb or your healthcare provider for further guidance.
For assistance, call Bristol-Myers Squibb at 1-800-XXX-XXXX or visit their website for more information.
Get notified about recalls in categories you care about.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg on October 10, 2025, due to failed stability testing. The recall affects capsules packaged in blister packs and sold nationwide. Consumers must stop using the product immediately and seek guidance from healthcare providers.